These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18240199)

  • 1. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
    Elliot MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Katasikis P; Brennan FM; Bijl H; Ghrayeb J; Woody JN
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S92-S101. PubMed ID: 18240199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
    Elliott MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Katsikis P; Brennan FM; Walker J; Bijl H; Ghrayeb J
    Arthritis Rheum; 1993 Dec; 36(12):1681-90. PubMed ID: 8250987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
    Charles P; Elliott MJ; Davis D; Potter A; Kalden JR; Antoni C; Breedveld FC; Smolen JS; Eberl G; deWoody K; Feldmann M; Maini RN
    J Immunol; 1999 Aug; 163(3):1521-8. PubMed ID: 10415055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
    Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
    Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
    Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
    J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
    Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
    Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
    Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
    Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of rheumatoid arthritis: the historical context.
    Moreland LW; Russell AS; Paulus HE
    J Rheumatol; 2001 Jun; 28(6):1431-52. PubMed ID: 11409142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of anti-TNF therapy for rheumatoid arthritis.
    Feldmann M
    Nat Rev Immunol; 2002 May; 2(5):364-71. PubMed ID: 12033742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.